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Abstract 
Oxygen-challenge imaging (OCI) involves transient hyperoxia applied during 
deoxyhemoglobin sensitive (T2*-weighted) magnetic resonance imaging (MRI), and has the 
potential to detect changes in brain oxygen extraction. In order to develop optimal practical 
protocols for OCI, we investigated the influence of oxygen concentration, cerebral blood 
flow change, pattern of oxygen administration and field strength on T2*-weighted signal. 
Eight healthy volunteers underwent multi-parametric MRI including OCI and arterial spin 
labelling (ASL) using two oxygen concentrations (target FiO2 of 100% and 60%) administered 
consecutively (two-stage challenge) at both 1.5T and 3T. There was a greater signal increase 
in grey matter compared to white matter during OC (p<0.002 at 3T, P<0.0001 at 1.5T) and at 
FiO2=100% compared to FiO2=60% in grey matter at both field strengths (p<0.02) and in 
white matter at 3T only (p=0.0314). Differences in the magnitude of signal change between 
1.5T and 3T did not reach statistical significance. Reduction of T2*-weighted signal to below 
baseline, after hyperoxia withdrawal, confounded interpretation of two-stage OCI. 
Reductions in cerebral blood flow did not obscure the T2*-weighted signal increases. In 
conclusion, the optimal protocol for further study should utilise target FiO2=100% during a 
single oxygen challenge. Imaging at both 1.5T and 3T is clinically feasible.  
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Background 
Respiratory challenge using transient inhalation of supplemental gas mixtures during 
magnetic resonance (MR) imaging may be a useful method to probe the metabolic state of 
brain tissue. A hyperoxic “challenge” administered whilst scanning with MR sequences 
sensitive to deoxyhemoglobin (T2*-weighted sequences), precipitates an increase in T2*-
weighted signal in healthy tissue, on the basis of a relative decrease in deoxyhemoglobin1. 
Our group has evaluated oxygen challenge imaging (OCI) in rodent models of stroke and in 
stroke patients2-8. In hypometabolic tissue - putative ischaemic core - diminished rises in 
T2*-weighted signal were observed4, 8. In rodent studies the exaggerated rise in T2*-
weighted signal intensity in putative ischemic penumbra compared to normal tissue8 is 
believed to result from increased deoxyhaemoglobin as a result of increased oxygen 
extraction fraction (OEF)9 compared to baseline, and high cerebral blood volume due to 
compensatory arteriolar vasodilatation.  
In this study we sought to; 
- Investigate the changes in T2*-weighted signal intensity in response to different inhaled 
oxygen concentrations  
- Compare one-stage oxygen challenge (OCI) to two-stage OCI 
- Explore the influence of hyperoxia on cerebral blood flow (CBF), and  
- Clarify the feasibility of imaging at different clinically relevant MRI field strengths.  
 
Methods 
Simulations 
Prior to the human studies, simulations were undertaken to predict T2*-weighted signal 
change in grey matter in relation to MR field strength, oxygen concentration, and tissue OEF 
using a previously published method10. This is based on a novel biophysical model of blood 
oxygen level dependant (BOLD) contrast with hyperoxia which accounts for the 
susceptibility of oxygen dissolved in plasma. This model assumes that the contrast agent 
does not change the baseline cerebral metabolic rate for oxygen (CMRO2) or OEF of the 
tissue being investigated. 
 
Subject Recruitment 
This study was approved by the West of Scotland Research Ethics Service (REC Reference 
12/WS/0200) and written informed consent was attained from all subjects. All experiments 
were performed in accordance with the Declaration of Helsinki and Good Clinical Practice. 
We recruited healthy adult volunteers ≥ 18 years. Exclusion criteria were a. Type II 
respiratory failure, b. Heart Failure, c. Hemodynamic instability including atrial fibrillation, d. 
CNS disease likely to affect hemodynamic response to oxygen e.g. previous stroke and e. 
Contraindications to MR including pregnancy, pacemakers, and ferromagnetic implants.  
 
Study Specific Procedures 
Basic demographics and details of medications, vasoactive drug use, and past medical 
history were recorded. Subjects were scanned using two separate MR scanners (GE Signa) of 
different field strengths (1.5T and 3T) on two separate days. Prior to scanning, subjects were 
asked to refrain from ingestion of caffeine or tobacco for 6 hours. Baseline blood pressure, 
heart rate and nail bed capillary oxygen saturations (SpO2) were measured using an MR 
compatible anaesthesia patient monitor (Veris® Vital Signs Monitor, MEDRAD, Indianola, 
PA).  
 
 
Gas Administration 
Subjects were fitted with an oxygen mask (Intersurgical Ltd, Ref 1141) for the duration of 
the MR examination. The expiratory ports were closed and used gauze swabs and tape to 
create a tight seal between the face and the mask. The mask was then connected to a 
specially designed unidirectional breathing circuit (Ref 2013014, Intersurgical Ltd) via a 
catheter mount (Intersurgical Ltd, Ref 3514). This prevents rebreathing. The breathing 
circuit was connected to an anaesthetic machine (Datex Ohmeda Aestiva /5 MRI) via a filter 
(Clear-Therm 3 HMEF, Luer Lock Port, Intersurgical, Ref 1541).  The fraction of inspired 
oxygen (FiO2) was varied between 21%, 60%, and 100% in either an ascending or descending 
sequence during T2*-weighted echoplanar imaging (EPI) and separate arterial spin labelling 
(ASL) sequences.  During the T2*-weighted sequence, medical air was alternated with 
hyperoxia in the following fashion: 
- air (2mins 13s), followed by 
- oxygen challenge 1 [OC1] (3mins), followed by 
- air (2mins), followed by 
- oxygen challenge 2 [OC2] (3mins), followed by 
- air (1min).   
In half of the subjects (subjects 2,3,6,7) oxygen was given with an FiO2 = 100% for OC1 and 
FiO2=60% for OC2 [descending protocol], and the sequence was reversed for the remaining 
half (subjects 1,5,8,9) [ascending protocol]. Heart rate, respiratory rate and SpO2 were 
recorded throughout. Inspired oxygen (FiO2, %), end tidal carbon dioxide (ETCO2,%) and end 
tidal oxygen (ETO2, %)  were monitored from a gas sampling  line connected to the MedRad 
monitor. 
 
MRI Protocols 
The MR Protocols for the 1.5T and 3T scanners are detailed in Table 1. The protocol for the 
3T scanner consisted of a T2*-weighted EPI sequence of 11mins and 12 seconds duration 
(TR = 2000ms, 332 volumes) as detailed in Table 1. This sequence was acquired with a 30° 
tilt relative to the AC-PC line in order to reduce artefact from nasal sinuses. The remainder 
of the 3T examination consisted of 3 pseudocontinuous arterial spin labelling (ASL) 
sequences acquired with normoxia (ASL21%) and then with the two different levels of 
hyperoxia in the order given during the EPI sequence (ASL60% and ASL100%).  Parameters for 
the ASL are also included in Table 1.  In addition, for each concentration of oxygen, seven 
images with fast low shot angle sequences were acquired at different flip angles to allow for 
correction of the effects of oxygen on T1-weighted signal for the ASL data. A 3D T1-weighted 
image of the whole brain was also acquired.   
 
Post Processing 
 
Generation of Time Series 
A Dell workstation was used for these analyses (Precision T3600, 8GB RAM, Intel Xeon 
2.8GHz). The T2*-weighted EPI data acquired at both 3T and 1.5T  were realigned to the first 
image using Statistical Parametric Mapping software (SPM8) which was run using the 
MATLAB R2013b platform. Next, the 3D T1-weighted imaging (preferably that acquired from 
the 3T examination) was skull stripped using the FSL Brain Extraction Tool11. Maps of grey 
and white matter were derived using the automated segmentation tool, FAST12. Default 
values were used for this analysis and a binarized map for grey matter and white matter was 
generated. The skull-stripped original T1-weighted image was transformed and co-
registered to the realigned T2*-weighted EPI data using windowed sinc interpolation using 
Analyze (v8.1, Mayo Clinic, USA). This process required manual manipulation to allow 
alignment. The transformation matrix was saved and applied to the grey and white matter 
maps. ‘Object maps’ delineating grey matter and white matter were overlaid onto the 
realigned T2*-weighted EPI data in Analyze. The anatomical coverage of the maps was 
truncated to cover from the level of the basal ganglia to the vertex in order to exclude 
regions from the posterior fossa. Time series of the raw data were then generated for all 
volumes of the time series. Wavelet transforms were then applied to smooth the data as 
previously described4, using R software (R Core Team, Vienna 2014; www.R-project.org). 
The resulting time series data were normalised to the baseline (volumes 0-62) using PRISM 
software (version 5.04 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com) and area under the curve (AUC) was calculated4. The baseline was 
defined as the mean of volumes 0-62 [0-124s], with AUC for the first oxygen challenge 
calculated from the data acquired from volumes 73-182 [146-364] (to allow for lag of gas 
delivery) and the AUC for the second oxygen challenge calculated from the data acquired 
from volumes 223-332 [446-664s]. 
 
Calculation of Change in Cerebral Blood Flow (CBF) and Cerebrovascular Resistance 
ASL data were separated into proton density and perfusion images using Image J (Rasband, 
W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, 
http://imagej.nih.gov/ij/, 1997-2014.). The 3D T1-weighted image, ASLFiO2_21% and 
ASLFiO2_100%  were coregistered to proton density map of ASLFiO2_21%  with 3D voxel 
registration using Analyze. The transformed T1-weighted image was skull stripped and 
segmented using the FSL brain extraction tool and FAST. T1 maps were calculated using 
MatLab on a pixel-by-pixel basis. The 3D T1-weighted image was segmented into grey 
matter, white matter and CSF. Binary grey matter masks were generated to extract the T1 
values of the grey matter, and an average value for T1 was obtained for each OC for each 
participant.  Quantitative CBF maps were then generated using an in house ‘macro’ for 
Image J with correction of T1-weighted signal using the averaged T1 values obtained in the 
grey matter and with the following equation [operator manual for optima edition 23 based 
software, GE Healthcare]: 
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where T1b is T1 of blood and is assumed to be 1.6s at 3T. T1t is the T1 value obtained on 
grey matter. ST is saturation time and was set to 2s. The partition coefficient λ, is set to the 
whole brain average, 0.9. The efficiency, ε, is a combination of both inversion efficiency (0.8) 
and background suppression efficiency (0.75) resulting in an overall efficiency of 0.6. PLD is 
the post labelling delay used for the ASL experiment. LT is the labelling duration set to 1.5s. 
PW is the perfusion weighted or the raw difference image. SFPW is the scaling factor of PW 
sequence. NEXPW is the number of excitations for PW images. The CBF is reported in units 
of ml/100g/min. 
Binarized grey matter masks were then applied to the CBF21%  map and whole brain grey 
matter CBF calculated. This was then repeated with the other co-registered ASL scans. To 
generate measurements of cerebrovascular reactivity the following formula was used in 
Microsoft Excel: Change in CBF = (Grey matter CBF100% – Grey matter CBF21%) / Grey matter 
CBF21%)  * 100. Cerebrovascular reactivity (CVR) was calculated by dividing change in CBF by 
change in ETO2.  
 
Statistical Analysis 
Statistical analyses were performed using StatsDirect software (v2.8.0, Cheshire UK, 2013; 
www.statsdirect.com). Prior to comparative analyses, normality was assessed using the 
Shapiro-Wilk test. Paired t-tests or Wilcoxon Signed Ranks Tests were used for normally 
distributed and non-normally distributed data, respectively. To compare all conditions 
simultaneously, a two way ANOVA test was employed. To assess the AUC of the T2*-
weighted signal change compared to baseline, and the percentage change in CBF compared 
to baseline, we employed a single sample t-test, using a value of ‘0’ as the baseline 
comparator.  Statistical significance was considered at p < 0.05 for two-way tests. 
 
 
Results 
 
Simulations 
Simulations were performed for blood vessels of different sizes at a normal brain oxygen 
extraction fraction (OEF) of 0.35; data for veins are the most relevant to this study (right 
hand side of each graph in Figure 1).  The predicted T2*-weighted signal change with 
hyperoxia was modelled for 1.5T and 3T (Figure 1). Simulations for grey matter predicted a 
greater magnitude of T2*-weighted signal change in response to hyperoxia at 3T compared 
to 1.5T but a detectable change at 1.5T also. Figure 1 also shows predicted differences in 
signal response with different concentrations of oxygen, dependent on the underlying tissue 
OEF. In general, simulations predicted a greater magnitude of T2*-weighted signal change in 
response to increasing concentrations of oxygen. In penumbral tissue with an OEF of 0.9, 
higher concentrations of oxygen were predicted to precipitate greater T2*-weighted signal 
change, but in hypometabolic tissue (OEF 0.10), a FiO2=100% would precipitate the least 
T2*-weighted signal intensity owing to the paradoxical effect of paramagnetic oxygen 
dissolved in plasma. 
 
 
Subjects 
We recruited 9 subjects, one of whom (subject 4) was excluded owing to intolerance of the 
MR scanner, therefore leaving 8 evaluable subjects.  There were five males and three 
females with median age 35y (range 31-39y). Four subjects were Caucasian, 3 were of South 
Asian origin, and one of Chinese origin. All subjects were in good health and none was taking 
vasoactive medications or smoking. Mean blood pressure was 120 (s.d. 11) / 77 (s.d. 11) 
with oxygen saturations measured by a pulse oximeter of ≥97% in all subjects. The ASL at 
FiO2=100% was not available for subject 5 since the scan was terminated due to scan 
intolerance, and ASL could not be analysed for any FiO2 in subject 9 owing to data 
corruption. We encountered technical problems with the proton density map for subject 8, 
so we were unable to derive quantitative CBF values for this subject, but we were still able 
to determine the percentage change in CBF using the CBF maps. Baseline and dynamic data 
for respiratory parameters and CBF are given in Table 2 and Supplemental Table 1, 
respectively. 
 
 
Time Series  
 
Graphs summarising the T2*-weighted signal time series are shown in Figure 2. The T2*-
weighted signal increased after oxygen challenge with both FiO2= 60% and FiO2=100% 
irrespective of order of administration. Withdrawal of hyperoxia was followed by a  
decrease in T2*-weighted signal below the original baseline –a  post oxygen-challenge (OC) 
“undershoot” - and remained below the original baseline until the next oxygen challenge or 
until the sequence finished. Therefore the projected duration of the undershoot beyond 120 
seconds after cessation of the OC is unclear. 
 
There was a significant increase in T2*-weighted signal intensity, as measured by AUC, at 
FiO2=100% in grey matter (p=0.002, at 3T; p<0.0001, at 1.5T) and white matter (p=0.007, at 
3T; p=0.002 at 1.5T).  There was also a significant increase in the AUC of the T2*-weighted 
signal intensity curve at the lower oxygen concentration of FiO2=60%., both in grey matter 
(p=0.001, at 3T; p=0.0003, at 1.5T) and in white matter (p=0.024, at 3T; p=0.02 at 1.5T). 
There was a highly statistical difference in the AUCs derived under all the different 
conditions when field strength, tissue type, and oxygen concentration was altered (AUC of 
T2*-weighted signal intensity curve from grey matter at FiO2=100% at 1.5T, from white 
matter at FiO2=100% at 1.5T, from grey matter at FiO2=60% at 1.5T, from white matter at 
FiO2= 60% at 1.5T, from grey matter at FiO2= 100% at 3T, from white matter at FiO2= 100% 
at 3T, from grey matter at FiO2=60% at 3T, and from white matter at FiO2=60% 3T, 
p<0.0001, two way ANOVA). 
There was a greater T2*-weighted signal change (AUC) precipitated by OC in grey matter 
compared to white matter (n=8 for all: FiO2=60% at 3T, p=0.0016; FiO2=100% at 3T, 
p=0.0011; FiO2=60% at 1.5T, p<0.0001; FiO2=100%  at 1.5T, p<0.0001). The AUCs during 
FiO2=100% were greater than those during FiO2=60%  in grey matter at both 1.5T and 3T 
(n=8 for all: p=0.019 at 3T, p=0.0072 at 1.5T) and in white matter at 3T (n=8, p=0.0314) but 
not at 1.5T (n=8, p=0.177).  
There was no statistical difference between the AUCs derived at 1.5T compared to 3T (n=8 
for all: for grey matter at FiO2=100%, p=0.72; for grey matter at FiO2=60%, p=0.30; for 
white matter at FiO2=100%, p=0.77, for white matter at FiO2=60%, p=0.45) in this small 
sample.  
There was no difference between the magnitude of AUCs measured from ascending and 
descending protocols for FiO2=60% or FiO2=100%. 
 
 
 
Cerebral Blood Flow 
 
In grey matter, mean CBF was 51ml/100g/min (s.d 12, n=6, Supplementary Table 1).  CBF 
was lower in all subjects at FiO2=100% (mean CBF =46 ml/100g/min, s.d. 14ml/100g/min; 
mean reduction =  -11%, s.d. 6% [p=0.008, two sided single sample t-test], Figure 3 and 
Table 2). At FiO2=60%, there was a reduction of CBF in 5 of 7 subjects (mean CBF  = 
50ml/100g/min , s.d. 14 ml/100g/min; reduction =mean - 3%, s.d. 6%) but this did not reach 
statistical significance (p=0.23, two sided single sample t-test). The difference in CBF at 
FiO2=100% compared to FiO2=60% was statistically significant (p=0.005, paired t-test). 
Neither change in CBF nor change in cerebrovascular resistance significantly correlated with 
AUC of the T2*-weighted signal at FiO2=100%  (CBF, p=0.29; CVR, p=0.07) or at FiO2=60%  
(CBF, p=0.55; CVR, p=0.85). Figure 3 shows that hyperoxia precipitated a reduction in CBF in 
subject 1, particularly at FiO2=100%, and this in turn lead to a reduction in cerebrovascular 
resistance (CVR) as shown by the CVR maps. This figure also shows a greater reduction in 
CBF with 100% O2 compared to 60% O2 in subject 1.   
 
Discussion 
This study aimed to compare different oxygen delivery protocols for OCI and determine the 
influence of possible factors confounding T2*-weighted signal change during OCI.  The T2*-
weighted signal change, as measured by the AUC of the time series of this parameter, was 
clearly positively influenced by increasing oxygen concentrations, and signal changes were 
greater in grey matter compared to white matter. This was despite demonstrated 
reductions in ETCO2, CBF and subsequently CVR which would be expected to attenuate this 
response. We did not find any evidence of paradoxical decreases in signal intensity, even in 
white matter. Two-stage OC was confounded by the “undershoot” of T2*-weighted signal 
after the first oxygen challenge to below baseline.  We observed a variable ETO2 between 
subjects after delivery of fixed concentration of hyperoxia, despite modifications of the 
masks to limit gas escape. Finally, OCI is feasible on 1.5T MRI scanners which are more 
widely available in the clinical setting. 
 
At a FiO2 of 100% at 3T we observed clearly detectable increases in T2*-weighted signal 
change in healthy brain tissue. Our finding that OCI induces greater change in T2*-weighted 
signal in grey matter compared to white matter is expected and reflects greater cerebral 
metabolic rate for oxygen (CMRO2) and cerebral blood volume in grey matter13. 
Nonetheless, smaller but detectable T2*-weighted signal increases in white matter suggests 
that OCI may even be able to distinguish normally metabolising from hypometabolic white 
matter. 
 
Variable inter-subject ETO2 is expected when a closed gas delivery system (which requires 
endotracheal intubation or tightly sealed face and nose masks) is impossible within the 
physical constraints of the head coil combined with subject claustrophobia. In the absence 
of a specially designed CE marked MRI-compatible mask, we used a standard oxygen mask 
with additional tape seal, and achieved an ETO2 of 50-85% at FiO2=100% despite variable 
subject tolerance, facial geometry and facial hair. Our goal was to evaluate OCI with a 
clinically compatible system, since this is a key factor in establishing the potential to 
translate the method to a clinical setting, particularly in acutely unwell patients. 
Absolute values for CBF derived from ASL should be interpreted with caution. The measured 
mean grey matter CBF of 51ml/100g/min is less that one would expect. Global (mean) CBF is 
accepted to be approximately 50ml/100g/min in young healthy volunteers, as determined 
by invasive experimental data13, 14.  Values for grey matter and white matter cerebral blood 
flow have been shown to be around 80ml/100g/min and 20ml/100g/min respectively, as 
determined by intra-arterial Xenon 133 injection techniques15. Therefore our technique 
likely underestimated grey matter CBF. Nonetheless, the observed mean reduction in CBF 
with hyperoxia of 11%, which was variable among subjects, ranging from 5% to 20% 
reduction, is consistent with literature reports of a mean reduction of 13-15% in global 
CBF13, 14, 16. Studies using phase contrast MRI have shown slightly greater reductions of up to 
27%17, 18 and one ASL study reported a mean reduction of 32.6%19. However, unlike others, 
our study corrected for the effect of hyperoxia on T1-weighted signal. As in our study, 
Watson et al showed significant variation of CBF reduction between subjects - 8.99% to 
26.7% -  using hyperoxia at 15l/min during phase contrast MR18. Bulte and colleagues found 
smaller reductions in CBF using ASL20 - a mean grey matter CBF reduction of 7% was 
demonstrated with FiO2=100%, and 4% at FiO2=60%. Our data also reflected this differential 
effect, with a higher CBF at FiO2=100% compared to FiO2=60%.   
The reduction in CBF and CVR due to hyperoxia which was observed in this study, and 
others, is a potential confounder for our technique. Reductions in CBF are anticipated to 
reduce T2*-weighted signal intensity, and therefore attenuate rather than exaggerate the 
T2*-weighted signal intensity increase seen with OCI. We cannot assume similar changes in 
CBF in those with disease states such as stroke, since autoregulation may be lost, and there 
may be variability between metabolic tissue compartments within the same subject.  Since 
the CBF changes due to hyperoxia are likely to be due to secondary hypocapnia, a potential 
solution is to use controlled isocapnic hyperoxia for OCI21. Whilst this is feasible for healthy 
volunteers, it is less practical for patient studies, especially those which study acutely unwell 
subjects, since sequential gas delivery systems are required. Therefore, if OCI is to become 
feasible for subjects who are unwell, further study of the magnitude and direction of change 
in CBF with standard OCI in patients with disordered brain metabolism is desirable, in order 
to determine potential confounds in such patients. 
 
Since high FiO2 was associated with larger T2* signal changes in healthy brain tissue, this 
approach is likely to be optimal for future OCI studies. Nonetheless, our current findings 
relate only to healthy subjects and adaptation of protocols might be appropriate in different 
disease states. Although under physiological conditions a target FiO2=100% yielded the 
largest T2*-weighted signal increases, simulations predict different effects of higher oxygen 
concentration on T2* signal at different OEFs. For example, it was predicted that in tissue 
with a reduced OEF (0.15), such as might be encountered in infarcted tissue after stroke, the 
highest oxygen concentration would give rise to the smallest increase in T2*-weighted 
signal. In practice, this might be due to reduced production of deoxyhaemoglobin secondary 
to oxidative metabolism, and increased predilection for paramagnetic oxygen to dissolve in 
plasma which would in turn precipitate a decrease in T2*-weighted signal intensity. This is 
consistent with animal experimental stroke data which showed negative changes in T2*-
weighted signal within the infarct 22. It is possible therefore, that the use of more than one 
oxygen concentration may tease out differences in tissue of varying states of hypometabolic 
activity.  For example, one might hypothesise that the tissue with an increase in T2*-
weighted signal intensity during FiO2=60%, but a decrease in signal at FiO2=100% shows 
more metabolic activity than tissue with negative changes at both oxygen concentrations, 
and less metabolic activity than tissue with increases at both oxygen concentrations. 
However, despite the potential attraction of further investigating this hypothesis with the 
two-stage OC, we noted a post-OC “undershoot”.  The reduced T2* signal baseline post-
oxygen challenge has been observed in rodent studies, both in healthy tissue and to a 
greater extent  in penumbra2. Whether this relates to vasomotor or metabolic changes, or a 
combination, is unclear, but persistent signal change for at least 1600s in rodents, if 
replicated in humans, makes dual OC impractical in most clinical settings. Potential 
explanations include rebound increases in CBV or transient increases in OEF as hyperoxia is 
withdrawn. Regardless of the cause, this change in baseline means that interpretation of the 
second OCI in our study needs to be cautious.  
 
Finally, we addressed the feasibility of OCI at 1.5T since this field strength is in widest clinical 
use. The small but non-statistically significant difference in T2*-weighted signal change due 
to hyperoxia between 1.5T and 3T is consistent with our simulations that predicted lower 
response at 1.5T compared to 3T. It is also compatible with previously observed lower 
signal-to-noise ratios at 1.5T compared to 3T and 7T in calibrated Blood Oxygen Level 
Dependant MRI experiments measuring the cerebral metabolic rate for oxygen23. It is 
possible that a larger number of subjects in our study would have yielded a difference which 
was statistically significant. Nonetheless, as a result of these data we conclude that although 
higher field strengths are preferable, OCI is feasible on 1.5T MR scanners, and therefore has 
the potential to be applied on most clinical MR scanners. 
 
The strengths of this study include the collection of a large number of real time respiratory 
and MR parameters from the subjects to allow a systematic evaluation of the influences on 
the OCI signal. In addition, we corrected for the effects of oxygen on T1-weighted signal to 
reduce confounding of the ASL-derived CBF data. Limitations of this study include the lack of 
measurement of baseline cerebral blood volume (CBV) or in change in CBV during 
respiratory challenge. Given that venous CBV is a major influence on T2*-weighted signal, 
such information would allow a greater understanding of the contributors to the signal 
attained during OC MRI.  Although we did measure the change in CBF and ETCO2, both of 
which were small, venous CBV measurements during OC MR should be considered in the 
future, after accurate MR measures of venous CBV have been validated. Next, we made the 
theoretical assumption that the hyperoxic contrast does not change the baseline metabolic 
activity of the tissue. However, this may not actually be the case, and hyperoxia has been 
shown to reduce peri-infarct depolarisations in experimental models of stroke24, and lactate 
production has been shown to be reduced during hyperoxia in human stroke25. Therefore, a 
hyperoxic contrast agent to measure metabolic activity may change the very parameter it is 
trying to measure, and this represents a potential confound in interpretation of results. 
Limitations of the application of the oxygen challenge technique included the use of a non-
closed system, which gave rise to variable ETO2 owing to vary degrees of mask fit. In 
addition, the potentially claustrophobic protocol meant that not all subjects completed the 
MR examination. We recognise potential challenges in performing this technique in patients 
who are acutely unwell and may be poorly tolerant of MR imaging. Finally, we also 
acknowledge the limited numbers of subjects in this study, which could limit statistical 
power. 
 
For future studies we will apply a single oxygen challenge. If using non-closed respiratory 
apparatus, we will aim for a FiO2=100%. Although 3T scanners are preferable, the lack of a 
3T scanner should not be a barrier. When feasible, one should continue to collect ETO2 and 
ETCO2 data as these parameters both may influence OCI results, but there is little suggestion 
in the available data that CBF changes influence T2* signal response in  healthy brain tissue. 
Creation of a specially designed CE marked mask may be of value for future studies, in order 
to increase the seal between mask and the face and reduce claustrophobia. In addition, 
beard shaving may be required if this technique is used in the clinical setting. Future studies 
should evaluate the influences of hyperoxia on T2*-weighted signal change in subjects with 
impaired autoregulation and in disease states such as acute stroke, since the effects of 
hyperoxia on blood flow changes, and in turn T2*-weighted signal, may be different in these 
cohorts. Specific analysis of the post-OC undershoot should be performed.  
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 1.5T Duration TR (ms) TE (ms) TI (ms) SG(ms) ST (ms) FA (ms) 
3D T1-weighted image - IR-FSPGR 1m43s 2162.3 21.056 750 1.4 1.4 10 
T2*-weighted sequence 11m13s 2000 22.4 * 3.5 3.5 80 
3.0T        
3D T1-weighted image  - BRAVO 4m2s 8.992 3.604 450 1.2 1.2 12 
T2-weighted FLAIR 3m20s 10000 144.072 2250 6.5 5 90 
T2*-weighted sequence 11m12s 2000 18.9 * 3.5 3.5 80 
ASL during normoxia (NEX=3) 4m42s 4864 10.076 2025 3.5 3.5 155 
T1 Mapping during concentration during normoxia 54s 5 0.8 * 2 2 -20,2,4,6,8,30 
ASL during first oxygen concentration (NEX=3) 4m42s 4864 10.076 2025 3.5 3.5 155 
T1 Mapping (SPGR) during first oxygen concentration 54s 5 0.8 * 2 2 -20,2,4,6,8,30 
ASL during second oxygen (NEX=3)concentration 4m42s 4864 10.076 2025 3.5 3.5 155 
T1 Mapping during second oxygen concentration 54s 5 0.8 * 2 2 -20,2,4,6,8,30 
 
Table 1. Details of MR Protocols at 1.5T and 3T 
ms= milliseconds, m=minutes, s=seconds, 3D = three dimensional, IR-FSPGR  = fast Spoiled Grass Sequence with inversion recovery preparation, 
BRAVO = brain volume imaging, FLAIR = fluid-attenuated inversion recovery, ASL = arterial spin labelling, NEX = number of excitations, SPGR = 
spoiled gradient echo. 
 
 Table 2. Summary of results for all subjects.  
Data acquired at a target FiO2=100% is given in the top section, and data acquired at a target of FiO2= 60% is given in the lower section. CVR = 
cerebrovascular resistance measured in units of (% ΔCBF / % ΔEtO2) where Δ = change. s.d. = standard deviation. FiO2 = fractional inspired 
oxygen, CBF = cerebral blood flow, ETCO2 = end tidal carbon dioxide, ETO2  = end tidal oxygen, AUC = area under the curve of the T2*-weighted 
signal intensity curve at 3T. (a) indicates ascending protocol, and (d) indicates descending protocol. * indicates a statistically significant 
increase compared to baseline conditions, **  indicates a statistically significant decrease compared to baseline conditions, and Ɨ  indicates 
where there was no statistically significant change compared to baseline conditions 
 
 
FiO2 ETO2 (%) Change in ETO2 (%) ETCO2 (%) Change in  ETCO2 (%) CVR Change in CBF (%) AUC 
 
Target FiO2=100% 
Subject 1(a) 99 75 57 4.7 -0.4 -0.35 -20 114 
Subject 2(d) 100 60 43 4 -0.6 -0.38 -16 52 
Subject 3(d) 95 55 38 5.2 -0.2 -0.15 -6 86 
Subject 5 (a) 95 64 47 4.3 -0.4 * * 115 
Subject 6(d) 100 85 68 5 -0.2 -0.07 -5 203 
Subject 7(d) 100 83 65 4.7 -0.2 -0.09 -6 145 
Subject 8(a) 96 56 40 4.5 -0.1 -0.33 -13 40 
Subject 9(a) 95 50 34 5.3 -0.3 * * 31 
Mean (s.d.) 98 (3) 66 (13.4)  49 (13)* 4.7 (0.45) -0.3 (0.16)** 
-0.23 
(0.14)** -11 (6)** 98 (58)* 
 
Target FiO2= 60% 
Subject 1(a) 61 47 29.3 4.8 -0.3 -0.31 -9 64 
Subject 2(d) 61 34 17 4.6 0 -0.47 -8 49 
Subject 3(d) 60 36 19 5.2 -0.2 -0.21 -4 29 
Subject 5(a) 64 46 29 4.4 -0.3 -0.20 -6 84 
Subject 6(d) 58 44 27.1 5 -0.2 0.07 2 56 
Subject 7(d) 60 50 32.6 4.8 -0.1 0.25 8 40 
Subject 8(a) 59 34 17.6 4.6 0 -0.28 -5 31 
Subject 9(a) 61 33 17 5.5 -0.1 * * 6 
Mean (s.d.) 61 (2) 41 (7) 24 (6.5)* 4.9 (0.36) -0.15 (0.12)** 
-0.17 
(0.24) Ɨ -3 (6)Ɨ 45 (23*) 
  
CBF (ml/100g/min) ETO2 (%) ETCO2 (%) 
 
Baseline 
Subject 1 37 18 5.1 
Subject 2 50 17 4.6 
Subject 3 40 17 5.4 
Subject 5 53 17 4.7 
Subject 6 71 17 5.2 
Subject 7 55 17 4.9 
Subject 8 * 16 4.6 
Subject 9 * 16 5.6 
Mean (s.d.) 51 (12) 17 (0.6) 5 (0.4) 
 
Supplemental Table 1. Baseline measurements from all subjects breathing air.  
Note that subject 4 did not tolerate any imaging and was therefore not included. Baseline CBF data were not available for subject 8 owing to 
technical issues with the proton density map, and CBF data were not available for subject 9. CBF = cerebral blood flow. ETO2  = end tidal 
oxygen,  ETCO2 = end tidal carbon dioxide 
 
 
 
 
 
 
Titles and legends to figures 
Figure 1. Dependence of T2*-weighted signal change on field strength, gas type and 
Oxygen Extraction Fraction (OEF). 
The figure shows simulations for the dependence of brain T2*-weighted signal change (% 
change relative to air) (y-axis) as a function of vessel diameter, vessel type, OEF and field 
strength. Data to the left of the first broken vertical line correspond to arteries, data 
between the vertical broken lines correspond to capillaries, and data to the right of the 
second vertical line correspond to veins. The diameter of vessels increases along the x-axis 
from the middle section (which represents the smallest vessels [capillaries]) in a leftward 
and rightward direction. Data from different gas types are colour coded according to the 
figure key. The top panel shows simulations which assume a normal OEF (0.35) at 1.5T, and 
the effect of field strength can be seen when comparing to the simulations for the same OEF 
at 3.0T, in the graph directly below it. The bottom panel shows the effect of changing OEF 
on T2*-weighted signal at 3.0T, with OEF increasing from left to right. The graph on the left 
shows data from a low OEF (0.10) as might be seen in infarct core, the middle graph shows a 
normal OEF and the graph on the right shows data from ‘penumbral’ OEF (0.9). 
 
 
 
Figure 2. T2*-weighted signal intensity curves. 
Data from both 3T  (top) and 1.5T (bottom) in both grey matter (left column) and white 
matter (right column) are shown, with data from ascending and descending protocols 
shown separately. In four subjects the oxygen was given with a FiO2 =100% for OC1 and 
FiO2=60% for OC2 [descending protocol], and the sequence was reversed for a second 
cohort of 4 subjects [ascending protocol]. The solid line data points show the mean data 
from 4 subjects and the grey lines show standard deviations. Broken vertical lines show the 
onset and offset of the first oxygen challenge, and the solid vertical lines show the same for 
the second oxygen challenge. 
 
Figure 3. Blood Flow and Cerebrovascular Resistance Maps  
Top panel show maps of cerebral blood flow (CBF) at FiO2 of 21%, 60%, and 100% from 
subject 1, running from left to right. The color scale indicates cerebral blood flow 
(ml/100g/min). The bottom panel shows cerebrovascular reactivity (CVR) maps from subject 
1 when alternating between FiO2 of 21% and 60% (bottom left) and between FiO2 21% and 
100% (bottom right). The color scale indicates percentage change in cerebral blood flow 
(the ‘-‘ sign indicates a reduction in cerebral blood flow) The maps show a reduction in 
cerebral blood flow with hyperoxia, which is more pronounced at FiO2 100% compared to 
FiO2 60%. The colour scale shows CVR (%).  
 



